National Resilience

National Resilience, also known as Resilience, is a biopharmaceutical manufacturing and technology company that provides end-to-end manufacturing and development solutions for diverse modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. It actively invests in developing new manufacturing technologies to expand access to complex medicines and supports partners through the full lifecycle from development to commercial supply. The company was incorporated in 2020 and is based in La Jolla, California.

Rahul Singhvi Ph.D

Co-Founder, CEO and Board Member

Olivia Zetter

Head of Government Affairs and AI Strategy

6 past transactions

PartnerSlate

Seed Round in 2023
PartnerSlate is an online platform facilitating strategic partnerships between food and beverage brands and contract manufacturers across North America. It streamlines the manufacturing process by connecting brands with reliable production partners, reducing sourcing delays, and enabling efficient market scaling of new products.

Swiftscale Biologics

Acquisition in 2021
Swiftscale Biologics is a healthcare service provider based in South San Francisco, California, founded in 2019. The company specializes in cell-free protein synthesis, focusing on rapid expression, high-throughput synthesis, and the production of complex proteins. Its innovative platform is designed to test and develop antibodies that inhibit the interaction between viral proteins and human host cells, effectively stopping ongoing coronavirus infections. By advancing these life-saving drugs, Swiftscale Biologics aims to enhance patient outcomes and improve overall health.

Cellevolve Bio

Seed Round in 2021
Cellevolve Bio is a development and commercialization company specializing in cell therapies aimed at neglected diseases. The company collaborates with innovators to transition early-stage clinical therapies into commercially available treatments, particularly for pediatric and rare diseases. By advancing these therapies into clinical development, Cellevolve aims to significantly enhance patient outcomes and provide expertise in cell therapy and clinical care.

bit.bio

Series B in 2021
Bit.bio specializes in applying computational principles to biology, focusing on developing a scalable platform capable of producing consistent batches of every human cell. This enables more accurate research, drug discovery, and cell therapy applications.

Garuda Therapeutics

Series A in 2021
Garuda Therapeutics is a biotechnology company focused on developing off-the-shelf hematopoietic stem cell therapies aimed at treating life-threatening blood, bone marrow, immune, and metabolic diseases. The company is dedicated to eliminating the reliance on donor or patient cells for blood stem cell transplants. Utilizing advanced technologies, including zebrafish, mice, and human-induced pluripotent stem cells, Garuda Therapeutics conducts research to clone and analyze novel genes and mechanisms critical for blood formation. This innovative approach is designed to provide patients with consistent, durable, and HLA-compatible transgene-free blood stem cell therapies, offering rapid and broad access to life-saving treatments.

Ology Bioservices

Acquisition in 2021
Ology Bioservices is an integrated biopharmaceutical company specializing in the development and manufacturing of biopharmaceutical products and medical devices. Founded in 1999 and restructured in 2017, the company operates as a contract development and manufacturing organization (CDMO), providing services that include preclinical and clinical development, formulation optimization, and cGMP manufacturing. Ology Bioservices supports a wide range of drug types, from small molecules to proteins and vaccines, enabling clients to access high-quality biopharmaceutical solutions efficiently and cost-effectively. The company is equipped to manufacture products in compliance with BSL-3 standards, ensuring that it can cater to various client needs within the biopharmaceutical sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.